$LPCN – Lipocine Prices $25 Million Underwritten Public Offering

LPCN stock

Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock SALT LAKE CITY, Jan. 26, 2021 /PRNewswire/ —Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock, offered at a price of $1.75 to the public. […]